If the fibrinolysis tests could be helpful in identifying the T2DM patients who should receive such therapy, this requires substantial research efforts to reach the following goals: characterization of the effect of low-dose FXa inhibitors on fibrinolysis in human plasma; identification of the clinical and biochemical determinants of the well and poor response to low-dose FXa inhibitors; and implementation of the global standard of testing fibrinolysis in T2DM patients by diabetologists and cardiologists before introducing anticoagulant drugs. Here, F10 is linked to type 2 diabetes mellitus.